- Visibility0
- Citations15
- Sentiment50
- Site quality67
- AI readiness29
AI assistants do not name Agenus in any of their 60 answers to everyday market questions. Its overall score is 27 out of 100, ranking 1,568th of 2,047 companies, below the typical company in its sector. The Agenus website passes 4 of 14 technical checks for how ready it is for AI tools.
We asked 15 unbranded questions about the technology market: none named Agenus. AI assistants named it in none of 60 answers. The typical technology company is named in 10.0% of answers. By how often it is named, Agenus ranks 236 of 273 in its sector.
Named fewer than three times in total. Read this as a sign that AI assistants rarely bring this company up, not as an exact comparison with its rivals.
Every dot is a company in the study. Hover one to see it; click to open its report.
This companySame sectorEvery other companyNever named
Five parts, each scored out of 100.
How often AI assistants name the company
How often AI uses the company's own website as a source
How positively AI describes the company
How well built the website's own pages are
How easily AI tools can read and use the website
Visibility is calculated from the answers on this page. How the score is built.
273 companies in this sector. The line on each bar is the typical company.
How the mentions in these answers were split between this company and its rivals
Answers naming it, out of answers received
What this website publishes for an AI agent to read, use and buy from, on a scale of six levels.
- 0
- 1
- 2
- 3
- 4
- 5
Level 0: Not yet agent-ready. Agents struggle to find basic information about the site.
- 2 of robots.txt, Sitemap, Link headers
Show every check, for your technical teamHide the checks
- study: 92.0%robots.txtNot met
Publish a valid robots.txt with crawl rules and a Sitemap line.
- study: 86.8%SitemapPassed
An XML sitemap listing the pages, ideally referenced from robots.txt.
- study: 0.3%Link headersNot met
Send Link headers such as rel="api-catalog" or rel="describedby" on the homepage.
- study: 5.5%DNS for AI DiscoveryNot present
Advertise agent endpoints with SVCB records under _agents.
- study: 1.9%Markdown negotiationNot met
Return a markdown version when asked with Accept: text/markdown, for example at the CDN.
- study: 25.1%llms.txtNot met
Publish an llms.txt with a short summary and the key links.
- study: 93.4%AI bot rulesPartly met
Add explicit robots.txt groups for the main AI crawlers.
- study: 1.4%Content SignalsNot met
Add a Content-Signal line for search, ai-input and ai-train to robots.txt.
- study: 0.2%Web Bot AuthNot present
Only relevant if you run your own agents or crawlers: publish a signing key directory.
- study: 0.3%API CatalogNot met
List public APIs in a linkset at /.well-known/api-catalog.
- study: 11.8%OAuth discoveryNot met
Publish OpenID Connect or OAuth server metadata under /.well-known.
- study: 10.3%OAuth Protected ResourceNot met
Serve protected resource metadata at /.well-known/oauth-protected-resource.
- study: 0.0%auth.mdNot met
Publish an auth.md describing how agents sign in.
- study: 0.2%MCP Server CardNot met
Offer an MCP server and publish its server card under /.well-known.
- study: 0.1%A2A Agent CardNot met
Publish an agent card at /.well-known/agent-card.json.
- study: 0.2%Agent SkillsNot met
Publish a skills index with the main tasks agents can do.
- study: 33.7%WebMCPCould not check
Register key actions such as search or cart as WebMCP tools.
- study: 0.1%ARD manifestNot met
Publish an ai-catalog.json listing every agent interface.
Score 15 of 100 · 97% of checks could run · checked on October 5, 2026 · www.agenusbio.com · 2,047 companies scanned
4 of 14 passed. This list is for your technical team. The percentage is how many companies in the study pass each check.
These 14 checks ran during the audit and are what the AI readiness part of the overall score counts. The scan above ran later and is stricter on Link headers and Markdown, so a check can pass here and not there.
Show the 14 checksHide them
- Passedrobots.txt publishedstudy: 85.0%
- PassedXML sitemapstudy: 73.2%
- PassedHTTP Link headers (RFC 8288)study: 29.0%
- Not metMarkdown content negotiationstudy: 8.3%
- Not metllms.txt publishedstudy: 21.7%
- PassedToken budget (page weight)study: 95.2%
- Not metExplicit AI bot rulesstudy: 13.0%
- Not metAPI Catalog (.well-known/api-catalog)study: 0.2%
- Not metOAuth Authorization Server discoverystudy: 10.1%
- Not metOAuth Protected Resource discoverystudy: 9.3%
- Not metMCP Server Cardstudy: 0.0%
- Not metA2A Agent Cardstudy: 0.0%
- Not metWebMCP toolsstudy: 4.2%
- Not metAgent Skills declaredstudy: 0.0%
How many times each website was listed as a source in these answers
In the study as US-listed.
- Which non-immune-based cancer treatments are most often used when immunotherapies are not an option?
- How can immune-priming mechanisms improve treatment durability in metastatic solid tumors?
- Immuno-oncology vs traditional chemotherapy: what are the main differences in treatment outcomes and side effects?
- How do checkpoint inhibitors compare to cancer vaccines in terms of effectiveness for solid tumors?
- What new combination therapies are being explored to increase the effectiveness of immuno-oncology treatments?
- What are common side effects of immune system activating cancer treatments and how are they managed?
- What are the main alternatives to immunotherapy for patients with metastatic colorectal cancer?
- Is investing in next-generation immunotherapy worth it for advanced cancer patients?
- Why might a patient not respond to an immuno-oncology therapy, and what options exist if there is no response?
- Which immunotherapy approaches are showing success in activating the immune system to target tumors?
- What are the most promising immuno-oncology therapies currently being researched for metastatic colorectal cancer?
- What is the typical cost range for immuno-oncology treatments in the US healthcare system?
- Are there financial assistance programs available to help cover the costs of immune system activating cancer therapies?
- Are novel immune system activating therapies effective for patients who have relapsed after standard treatments?
- What role do immune-based therapies play in personalized cancer treatment plans?
Columns, left to right: OpenAI, Claude, Perplexity, Gemini. The AI assistants often disagree. Across the study, on 40% of the questions where a company is named, only one of the four names it.